ODYY
Odyssey Health, Inc.0.0330
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.30MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
8-K
10-K
FY2025 results
Odyssey Health reported a net loss of $1.74 million for FY2025 ended July 31, 2025, widening from $0.84 million in FY2024 due to the absence of a $16.4 million gain on asset sales to Oragenics, though general and administrative expenses dropped 51% to $1.02 million amid reduced activity. No revenue was generated in either year, with research and development costs at zero in FY2025 after suspending projects like CardioMap and prioritizing Save-A-Life pending funding. Q4 FY2025 saw $69,787 in proceeds from selling Oragenics common stock, providing a liquidity boost, while the company ended with $1.98 million in debt and a $6.95 million working capital deficit. Liquidity remains strained with $19,084 in cash, supported by a $300,000 note issuance, but ongoing losses signal persistent funding needs. No annual guidance was disclosed. Substantial doubt persists on going concern amid regulatory and capital risks.
8-K
Odyssey secures BreastCheck rights
Odyssey Health, through subsidiary Odyssey Medical Devices, signed a master technology sub-license agreement on October 14, 2025, with NeuRX Health for exclusive worldwide rights to the FDA-registered BreastCheck®, a 15-minute at-home non-invasive test detecting breast abnormalities via temperature differences. The deal grants full access to intellectual property, know-how, and regulatory approvals for commercialization, with consideration tied to a percentage of equity line draws and future royalties per unit sold, pending closing conditions by October 30, 2025. This bolsters Odyssey's medtech portfolio amid rising breast cancer cases, yet hinges on funding and IP enforcement. Risks include third-party claims on the technology.
8-K
Odyssey Health raises $100K note
Odyssey Health secured $100,000 via a promissory note from accredited investor Peter D'Arruda, effective October 1, 2025, with 18% annual interest due in full by September 30, 2026. The deal includes a warrant for 100,000 common shares at $0.10 each, exercisable over five years. This infusion bolsters short-term liquidity. Yet dilution looms if warrants convert.
IPO
Employees
Sector
Industry
ADGM
Adagio Medical Holdings, Inc
1.18+0.35
BWAY
Brainsway Ltd.
16.87-0.47
CBLL
CeriBell, Inc.
21.99+0.09
COCH
Envoy Medical, Inc.
0.72-0.03
HSCS
HeartSciences Inc.
2.31-0.16
HSDT
Solana Company
3.10+0.06
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
INSP
Inspire Medical Systems, Inc.
115.51-3.75
PMI
Picard Medical, Inc.
2.30-0.13
VYCO
Vycor Medical, Inc.
0.16+0.00